Antoine Yver

Independent director
Antoine Yver - Independent director at the board of Directors of Sanofi and Member of the Scientific Committee
Antoine Yver, Independent director

At a Glance

Date of birth

January 31, 1958


French, American, Swiss

First elected or appointed

May 2022

Term expires

General Meeting 2025

Education and Business Experience

Antoine Yver was in charge of the Development of Centessa Pharmaceuticals, Ltd. as Chairman in 2021 and 2022. 

He began his oncology development career at Rhône Poulenc Rorer Inc. in 1990. In 1999, he joined the Aventis Group as Senior Director, Oncology Global Clinical Development. In 2005, he was appointed Senior Director of Oncology at Johnson & Johnson* and in 2006, Executive Director of Oncology at Schering-Plough.

From 2009 to 2016, he led global oncology development at AstraZeneca*, delivering TAGRISSO and LYNPARZA, including Senior Vice President, GMD Head of Oncology and Lead, China GMD (2013-2016). Subsequently, he was Executive Vice President, Global Head of Oncology Research and Development at Daiichi Sankyo* and developed ENHERTU. 

Antoine Yver is a former intern in medicine at the Hôpitaux de Paris (AIHP) as well as a former assistant at the Hôpitaux de Paris in pediatrics and oncology and former head of clinic at the Universities. He is a Doctor of Medicine (MD) and Pediatrics from the University of Paris-Sud 11.
He also obtained a Master's degree in Immunology from the University of Paris.

Contact information

46, avenue de la Grande Armée - 75017 Paris (France)

Directorships & Appointments

Inside the Sanofi Group

Independent director

Chairman of the Scientific Committee

Member of the Strategy Committee

Outside the Sanofi Group

Spotlight Therapeutics: Board Member

* Listed company

Meet the Sanofi Board of Directors

Frédéric Oudéa - Chairman of the Board of Directors

Frédéric Oudéa

Chairman of the Board of Directors